NCT02672345View on ClinicalTrials.gov

Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Inflammatory Response
Interventions
DRUG

Sevoflurane

The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.

Trial Locations (1)

01423020

Thiago Augusto Azevedo Maranhão Cardoso, São Paulo

All Listed Sponsors
lead

Instituto Dante Pazzanese de Cardiologia

OTHER

NCT02672345 - Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB | Biotech Hunter | Biotech Hunter